Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

gilead.com

Headquarters: Foster City, United States
Founded year: 1987
Company type: Public company
Number of employees: 10,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Gilead Sciences (Gilead)

In short: Gilead reported 10% revenue growth in Q2 2026 and secured expanded regulatory approvals for its oncology and HIV portfolios.

Company announcements

Yesterday Gilead

Gilead partners with PAHO to expand lenacapavir access in Latin America and the Caribbean

The agreement uses PAHO's Regional Revolving Funds to support country-led adoption across 14 nations.

August 24 Gilead

Gilead receives European approval for Trodelvy plus Keytruda in first-line metastatic TNBC

The European Commission grants marketing authorization for the combination therapy, establishing Trodelvy as the first and only ADC approved across all PD-L1 status patients.

August 4 Gilead

Gilead announces second quarter 2026 financial results

Product sales excluding Veklury rose 10% to $7.6 billion, driven by HIV portfolio, Trodelvy and Livdelzi. Diluted loss per share was $(8.45) due to acquisition-related charges.

July 24 Gilead

CHMP recommends Gilead's Trodelvy plus Keytruda for first-line TNBC

The positive opinion based on Phase 3 ASCENT-04 study showed 35% reduced risk of progression or death in PD-L1 positive patients.

Media coverage

Yesterday Citeline

Gilead HIV Drug Dispute: Canadian Court Leaves ‘Door Open’ To Novel Liability Claims

A Canadian court has refused to dismiss an ongoing class action lawsuit against Gilead Sciences over alleged negligence claims relating to its HIV drug, a...

September 12 Fierce Pharma

Merck, Gilead's failed Trodelvy lung cancer trial shows better China results

The fact that Gilead Sciences' Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and Gilead's failed Trodelvy first-line...

September 11 Yahoo Finance

Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing...

September 10 BMJ

Lenacapavir: Gilead is urged to change price after NHS rejects HIV drug owing to cost

HIV drug lenacapavir, a twice yearly injectable pre-exposure prophylaxis (PrEP), has been rejected by the National Institute for Health and Care Excellence (NICE). In draft...

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gilead competitors & trending companies

Browse news for competitors to Gilead and other trending companies.